{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T10:07:44Z","timestamp":1793614064245,"version":"4.5.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-74749-y","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T13:21:15Z","timestamp":1733232075000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Circulating prolactin levels and the effect of dopaminergic agonists in systemic lupus erythematosus: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"14","author":[{"given":"\u00c1lida Alves","family":"dos Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Faria","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Louren\u00e7o","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucilia Domingues Casulari","family":"da Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Augusto Casulari Roxo","family":"da Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8454-5504","authenticated-orcid":false,"given":"Ang\u00e9lica Amorim","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"74749_CR1","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/S0140-6736(14)60128-8","volume":"384","author":"L Lisnevskaia","year":"2014","unstructured":"Lisnevskaia, L., Murphy, G. & Isenberg, D. Systemic lupus erythematosus. Lancet. 384, 1878\u20131888 (2014).","journal-title":"Lancet"},{"key":"74749_CR2","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1136\/ard-2022-223741","volume":"82","author":"MK Crow","year":"2023","unstructured":"Crow, M. K. Pathogenesis of systemic lupus erythematosus: Risks, mechanisms and therapeutic targets. Ann. Rheum. Dis. 82, 999\u20131014 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"74749_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0961203318815768","volume":"28","author":"EAA Christou","year":"2019","unstructured":"Christou, E. A. A., Banos, A., Kosmara, D., Bertsias, G. K. & Boumpas, D. T. Sexual dimorphism in SLE: Above and beyond sex hormones. Lupus. 28, 3\u201310 (2019).","journal-title":"Lupus"},{"key":"74749_CR4","doi-asserted-by":"publisher","first-page":"1142723","DOI":"10.3389\/fimmu.2023.1142723","volume":"14","author":"RG Lahita","year":"2023","unstructured":"Lahita, R. G. Sex and gender influence on immunity and autoimmunity. Front. Immunol. 14, 1142723 (2023).","journal-title":"Front. Immunol."},{"key":"74749_CR5","first-page":"855","volume":"77","author":"AM Eudy","year":"2018","unstructured":"Eudy, A. M. et al. Effect of pregnancy on disease flares in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 77, 855\u2013860 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"74749_CR6","doi-asserted-by":"publisher","first-page":"906475","DOI":"10.3389\/fmed.2022.906475","volume":"9","author":"JW Kim","year":"2022","unstructured":"Kim, J. W., Kim, H. A., Suh, C. H. & Jung, J. Y. Sex hormones affect the pathogenesis and clinical characteristics of systemic lupus erythematosus. Front. Med. (Lausanne). 9, 906475 (2022).","journal-title":"Front. Med. (Lausanne)"},{"key":"74749_CR7","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41574-019-0194-6","volume":"15","author":"V Bernard","year":"2019","unstructured":"Bernard, V., Young, J. & Binart, N. Prolactin \u2014 A pleiotropic factor in health and disease. Nat. Rev. Endocrinol. 15, 356\u2013365 (2019).","journal-title":"Nat. Rev. Endocrinol."},{"key":"74749_CR8","doi-asserted-by":"publisher","first-page":"1015520","DOI":"10.3389\/fendo.2022.1015520","volume":"13","author":"R Pirchio","year":"2022","unstructured":"Pirchio, R., Graziadio, C., Colao, A., Pivonello, R. & Auriemma, R. S. Metabolic effects of prolactin. Front. Endocrinol. (Lausanne). 13, 1015520 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"74749_CR9","doi-asserted-by":"publisher","first-page":"1016427","DOI":"10.3389\/fimmu.2022.1016427","volume":"13","author":"MV Legorreta-Haquet","year":"2022","unstructured":"Legorreta-Haquet, M. V., Santana-S\u00e1nchez, P., Ch\u00e1vez-S\u00e1nchez, L. & Ch\u00e1vez-Rueda, A. K. The effect of prolactin on immune cell subsets involved in SLE pathogenesis. Front. Immunol. 13, 1016427 (2022).","journal-title":"Front. Immunol."},{"key":"74749_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.autrev.2007.11.018","volume":"7","author":"LJ Jara","year":"2008","unstructured":"Jara, L. J., Benitez, G. & Medina, G. Prolactin, dendritic cells, and systemic lupus erythematosus. Autoimmun. Rev. 7, 251\u2013255 (2008).","journal-title":"Autoimmun. Rev."},{"key":"74749_CR11","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1191\/096120301717164994","volume":"10","author":"LJ Jara","year":"2001","unstructured":"Jara, L. J., Vera-Lastra, O., Miranda, J. M., Alcala, M. & Alvarez-Nemegyei, J. Prolactin in human systemic lupus erythematosus. Lupus. 10, 748\u2013756 (2001).","journal-title":"Lupus"},{"key":"74749_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/rheumatology\/kei115","volume":"45","author":"A Lea\u00f1os-Miranda","year":"2006","unstructured":"Lea\u00f1os-Miranda, A. & C\u00e1rdenas-Mondrag\u00f3n, G. Serum free prolactin concentrations in patients with systemic lupus erythematosus are associated with lupus activity. Rheumatol. (Oxford). 45, 97\u2013101 (2006).","journal-title":"Rheumatol. (Oxford)"},{"key":"74749_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s12016-011-8256-0","volume":"42","author":"H Orbach","year":"2012","unstructured":"Orbach, H. et al. Prolactin and autoimmunity: Hyperprolactinemia correlates with serositis and anemia in SLE patients. Clin. Rev. Allergy Immunol. 42, 189\u2013198 (2012).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"74749_CR14","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1177\/0961203314531083","volume":"23","author":"MF Ugarte-Gil","year":"2014","unstructured":"Ugarte-Gil, M. F. et al. High prolactin levels are independently associated with damage accrual in systemic lupus erythematosus patients. Lupus. 23, 969\u2013974 (2014).","journal-title":"Lupus"},{"key":"74749_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.4081\/reumatismo.2018.1075","volume":"70","author":"WA Wan Asyraf","year":"2018","unstructured":"Wan Asyraf, W. A. et al. The association between serum prolactin levels and interleukin-6 and systemic lupus erythematosus activity. Reumatismo. 70, 241\u2013250 (2018).","journal-title":"Reumatismo"},{"key":"74749_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.autrev.2014.11.005","volume":"14","author":"M Costanza","year":"2015","unstructured":"Costanza, M., Binart, N., Steinman, L. & Pedotti, R. Prolactin: A versatile regulator of inflammation and autoimmune pathology. Autoimmun. Rev. 14, 223\u2013230 (2015).","journal-title":"Autoimmun. Rev."},{"key":"74749_CR17","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1177\/0961203317693094","volume":"26","author":"GG Song","year":"2017","unstructured":"Song, G. G. & Lee, Y. H. Circulating prolactin level in systemic lupus erythematosus and its correlation with disease activity: A meta-analysis. Lupus. 26, 1260\u20131268 (2017).","journal-title":"Lupus"},{"key":"74749_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Syst. Rev. 10, 89 (2021).","journal-title":"Syst. Rev."},{"key":"74749_CR19","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup, D. F. et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis of Observational studies in Epidemiology (MOOSE) group. Jama. 283, 2008\u20132012 (2000).","journal-title":"Jama"},{"key":"74749_CR20","doi-asserted-by":"crossref","unstructured":"Tufanaru, C., Aromataris, M. Z., Campbell, E. & Hopp, J. L. Chap. 3: Systematic Reviews of Effectiveness (ed Munn, Z., Aromataris, E.) (2020).","DOI":"10.46658\/JBIRM-17-03"},{"key":"74749_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control Clin. Trials. 7, 177\u2013188 (1986).","journal-title":"Control Clin. Trials"},{"key":"74749_CR22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1177\/0013164496056003004","volume":"56","author":"MT Rupinski","year":"1996","unstructured":"Rupinski, M. T. & Dunlap, W. P. Approximating Pearson product-moment correlations from Kendall\u2019s tau and Spearman\u2019s rho. Educ. Psychol. Meas. 56, 419\u2013429 (1996).","journal-title":"Educ. Psychol. Meas."},{"key":"74749_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1196\/annals.1423.031","volume":"1110","author":"LJ Jara","year":"2007","unstructured":"Jara, L. J. et al. Bromocriptine during pregnancy in systemic lupus erythematosus: A pilot clinical trial. Ann. N Y Acad. Sci. 1110, 297\u2013304 (2007).","journal-title":"Ann. N Y Acad. Sci."},{"key":"74749_CR24","first-page":"282","volume":"42","author":"SER Walker","year":"1999","unstructured":"Walker, S. E. R. et al. Treatment of active systemic lupus erythematosus (SLE) with the prolactin (PRL) lowering drug, bromocriptine (BC): Comparison with hydroxichloquine (HC) in a randozimed blinded one-year study. Arthritis Rheumatol. 42, 282 (1999).","journal-title":"Arthritis Rheumatol."},{"key":"74749_CR25","first-page":"621","volume":"42","author":"XY Yang","year":"2003","unstructured":"Yang, X. Y. et al. Efficacy of oral bromocriptine in protecting the postpartum systemic lupus erythematosus patients from disease relapse. Zhonghua Nei Ke Za Zhi. 42, 621\u2013624 (2003).","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"74749_CR26","first-page":"629","volume":"23","author":"D Buskila","year":"1996","unstructured":"Buskila, D., Lorber, M., Neumann, L., Flusser, D. & Shoenfeld, Y. No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus. J. Rheumatol. 23, 629\u2013632 (1996).","journal-title":"J. Rheumatol."},{"key":"74749_CR27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s100670050075","volume":"18","author":"DM Chang","year":"1999","unstructured":"Chang, D. M., Chang, C. C., Kuo, S. Y., Chu, S. J. & Chang, M. L. Hormonal profiles and immunological studies of male lupus in Taiwan. Clin. Rheumatol. 18, 158\u2013162 (1999).","journal-title":"Clin. Rheumatol."},{"key":"74749_CR28","first-page":"1569","volume":"17","author":"M Folomeev","year":"1990","unstructured":"Folomeev, M. et al. Prolactin levels in men with SLE and RA. J. Rheumatol. 17, 1569\u20131570 (1990).","journal-title":"J. Rheumatol."},{"key":"74749_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1479-8077.2006.00205.x","volume":"9","author":"A Haghighi","year":"2006","unstructured":"Haghighi, A. & Lahmi, F. Hyperprolactinemia in patients with systemic lupus erythematosus: correlation with disease activity. APLAR J. Rheumatol. 9, 227\u2013231 (2006).","journal-title":"APLAR J. Rheumatol."},{"key":"74749_CR30","first-page":"57","volume":"28","author":"T Iqbal","year":"2017","unstructured":"Iqbal, T., Haseen, S. D., Sheikh, S. I., Imtiaz, F. & Ahsan, M. Serum prolactin: Biochemical parameter for assessing disease severity among rheumatoid arthritis and systemic lupus erythematosus. Med. Forum Mon. 28, 57\u201360 (2017).","journal-title":"Med. Forum Mon."},{"key":"74749_CR31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1756-185X.2008.00378.x","volume":"11","author":"M Jokar","year":"2008","unstructured":"Jokar, M., Maybodi, N. T., Amini, A. & Fard, M. H. Prolactin and macroprolactin in patients with systemic lupus erythematosus. Int. J. Rheum. Dis. 11, 257\u2013262 (2008).","journal-title":"Int. J. Rheum. Dis."},{"key":"74749_CR32","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00296-011-2211-5","volume":"33","author":"M Karimifar","year":"2013","unstructured":"Karimifar, M., Tahmasebi, A., Bonakdar, Z. S. & Purajam, S. Correlation of serum prolactin levels and disease activity in systematic lupus erythematosus. Rheumatol. Int. 33, 511\u2013516 (2013).","journal-title":"Rheumatol. Int."},{"key":"74749_CR33","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1191\/096120300680198926","volume":"9","author":"CC Mok","year":"2000","unstructured":"Mok, C. C. & Lau, C. S. Profile of sex hormones in male patients with systemic lupus erythematosus. Lupus. 9, 252\u2013257 (2000).","journal-title":"Lupus"},{"key":"74749_CR34","first-page":"2357","volume":"25","author":"CC Mok","year":"1998","unstructured":"Mok, C. C., Lau, C. S., Lee, K. W. & Wong, R. W. Hyperprolactinemia in males with systemic lupus erythematosus. J. Rheumatol. 25, 2357\u20132363 (1998).","journal-title":"J. Rheumatol."},{"key":"74749_CR35","first-page":"336","volume":"17","author":"D Raeisi","year":"2018","unstructured":"Raeisi, D., Zare, M. E., Nasir, A., Sherkatolabbasieh, H. & Shafeizadeh, S. Sex hormones and prolactin levels and their association with anti cardiolipin antibody in patients with systemic lupus erythematosus. Iran. J. Allergy Asthma Immunol. 17, 336\u2013345 (2018).","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"74749_CR36","first-page":"110","volume":"4","author":"M Rastin","year":"2007","unstructured":"Rastin, M. et al. Sex hormones and peripheral white blood cell subsets in systemic lupus erythematosus patients. Iran. J. Immunol. 4, 110\u2013115 (2007).","journal-title":"Iran. J. Immunol."},{"key":"74749_CR37","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1007\/s00296-006-0129-0","volume":"26","author":"Z Rezaieyazdi","year":"2006","unstructured":"Rezaieyazdi, Z. & Hesamifard, A. Correlation between serum prolactin levels and lupus activity. Rheumatol. Int. 26, 1036\u20131039 (2006).","journal-title":"Rheumatol. Int."},{"key":"74749_CR38","first-page":"436","volume":"26","author":"SS Shabanova","year":"2008","unstructured":"Shabanova, S. S., Ananieva, L. P., Alekberova, Z. S. & Guzov, I. I. Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 26, 436\u2013441 (2008).","journal-title":"Clin. Exp. Rheumatol."},{"key":"74749_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejr.2011.03.001","volume":"33","author":"D Shahin","year":"2011","unstructured":"Shahin, D. Thrombocytopenia and leukocytosis are independent predictors of hyperprolactinemia in systemic lupus erythematosus patients. Egypt. Rheumatol. 33, 77\u201383 (2011).","journal-title":"Egypt. Rheumatol."},{"key":"74749_CR40","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1177\/0961203315622276","volume":"25","author":"J Yang","year":"2016","unstructured":"Yang, J., Li, Q., Yang, X. & Li, M. Increased serum level of prolactin is related to autoantibody production in systemic lupus erythematosus. Lupus. 25, 513\u2013519 (2016).","journal-title":"Lupus"},{"key":"74749_CR41","first-page":"19223","volume":"8","author":"X Zhu","year":"2015","unstructured":"Zhu, X., Xu, J., Li, S., Huang, W. & Li, F. Role of abnormal anterior pituitary hormones-growth hormone and prolactin in active systemic lupus erythematosus. Int. J. Clin. Exp. Med. 8, 19223\u201319231 (2015).","journal-title":"Int. J. Clin. Exp. Med."},{"key":"74749_CR42","first-page":"537","volume":"18","author":"C Aulestia","year":"2016","unstructured":"Aulestia, C., De Zubir\u00eda, A., Granados, C., Su\u00e1rez, J. & Cervera, R. Prolactin and estradiol profile in a cohort of Colombian women with systemic lupus erythematosus. Isr. Med. Assoc. J. 18, 537\u2013541 (2016).","journal-title":"Isr. Med. Assoc. J."},{"key":"74749_CR43","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/1529-0131(200106)44:6<1331::AID-ART225>3.0.CO;2-Q","volume":"44","author":"J Cruz","year":"2001","unstructured":"Cruz, J., Avi\u00f1a-Zubieta, A., de la Mart\u00ednez, G., Clapp, C. & Lavalle, C. Molecular heterogeneity of prolactin in the plasma of patients with systemic lupus erythematosus. Arthritis Rheum. 44, 1331\u20131335 (2001).","journal-title":"Arthritis Rheum."},{"key":"74749_CR44","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1479-8077.2006.00206.x","volume":"9","author":"L Dai","year":"2006","unstructured":"Dai, L. et al. Cerebrospinal fluid and serum prolactin in systemic lupus erythematosus with and without central nervous system involvement. APLAR J. Rheumatol. 9, 232\u2013237 (2006).","journal-title":"APLAR J. Rheumatol."},{"key":"74749_CR45","first-page":"237","volume":"57","author":"AE G\u00f3mez-Hern\u00e1ndez","year":"2016","unstructured":"G\u00f3mez-Hern\u00e1ndez, A. E., Garc\u00eda-Mac Gregor, E. J. & Garc\u00eda-Montiel, D. A. Evaluaci\u00f3n De Los valores s\u00e9ricos de prolactina en lupus eritematoso sist\u00e9mico. Invest. Cl\u00edn.. 57, 237\u2013245 (2016).","journal-title":"Invest. Cl\u00edn."},{"key":"74749_CR46","first-page":"22","volume":"1","author":"R G\u00f3mez-P\u00e9rez","year":"2003","unstructured":"G\u00f3mez-P\u00e9rez, R., Roa, R. & Uzc\u00e1tegui, L. Prolactina s\u00e9rica en pacientes con lupus eritematoso sist\u00e9mico. Rev. Venez. Endocrinol. Metab.. 1, 22\u201326 (2003).","journal-title":"Rev. Venez. Endocrinol. Metab."},{"key":"74749_CR47","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/00000441-199204000-00003","volume":"303","author":"LJ Jara","year":"1992","unstructured":"Jara, L. J. et al. Hyperprolactinemia in systemic lupus erythematosus: Association with disease activity. Am. J. Med. Sci. 303, 222\u2013226 (1992).","journal-title":"Am. J. Med. Sci."},{"key":"74749_CR48","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.arcmed.2004.11.007","volume":"36","author":"CK Kramer","year":"2005","unstructured":"Kramer, C. K., Tourinho, T. F. & de Castro, W. P. & Da Costa Oliveira, M. Association between systemic lupus erythematosus, rheumatoid arthritis, hyperprolactinemia and thyroid autoantibodies. Arch. Med. Res. 36, 54\u201358 (2005).","journal-title":"Arch. Med. Res."},{"key":"74749_CR49","first-page":"268","volume":"14","author":"C Lavalle","year":"1987","unstructured":"Lavalle, C. et al. Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus. J. Rheumatol. 14, 268\u2013272 (1987).","journal-title":"J. Rheumatol."},{"key":"74749_CR50","first-page":"866","volume":"28","author":"DB Paraiba","year":"2010","unstructured":"Paraiba, D. B. et al. Lymphocytic prolactin does not contribute to systemic lupus erythematosus hyperprolactinemia. Clin. Exp. Rheumatol. 28, 866\u2013872 (2010).","journal-title":"Clin. Exp. Rheumatol."},{"key":"74749_CR51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2174\/1871530315666151020101518","volume":"16","author":"C Toffoli Ribeiro","year":"2016","unstructured":"Toffoli Ribeiro, C., Louzada J\u00fanior, P. & de S\u00e1, M. F. Correlation between systemic lupus erythematosus activity and plasma levels of monomeric prolactin and macroprolactin. Endocr. Metab. Immune Disord Drug Targets. 16, 21\u201327 (2016).","journal-title":"Endocr. Metab. Immune Disord Drug Targets"},{"key":"74749_CR52","first-page":"2140","volume":"30","author":"O Vera-Lastra","year":"2003","unstructured":"Vera-Lastra, O. et al. Correlation of prolactin serum concentrations with clinical activity and remission in patients with systemic lupus erythematosus. Effect of conventional treatment. J. Rheumatol. 30, 2140\u20132146 (2003).","journal-title":"J. Rheumatol."},{"key":"74749_CR53","first-page":"1514","volume":"34","author":"G C\u00e1rdenas-Mondrag\u00f3n","year":"2007","unstructured":"C\u00e1rdenas-Mondrag\u00f3n, G., Ulloa-Aguirre, A., Isordia-Salas, I., Goffin, V. & Lea\u00f1os-Miranda, A. Elevated serum bioactive prolactin concentrations in patients with systemic lupus erythematosus are associated with disease activity as disclosed by homologous receptor bioassays. J. Rheumatol. 34, 1514\u20131521 (2007).","journal-title":"J. Rheumatol."},{"key":"74749_CR54","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1191\/096120398678920299","volume":"7","author":"C Ferreira","year":"1998","unstructured":"Ferreira, C. et al. Plasma homovanillic acid and prolactin in systemic lupus erythematosus. Lupus. 7, 392\u2013397 (1998).","journal-title":"Lupus"},{"key":"74749_CR55","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1191\/096120301678646173","volume":"10","author":"A Hrycek","year":"2001","unstructured":"Hrycek, A., Cie\u015blik, P., Tustanowski, J., Nowak, S. & Jedynak, P. Selected serum cytokines in systemic lupus erythematosus treated with quinagolide. Lupus. 10, 424\u2013430 (2001).","journal-title":"Lupus"},{"key":"74749_CR56","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/08916930701306817","volume":"40","author":"A Hrycek","year":"2007","unstructured":"Hrycek, A., Pochopie\u0144-Kenig, G. & Scieszka, J. Selected acute phase proteins and interleukin-6 in systemic lupus erythematosus patients treated with low doses of quinagolide. Autoimmunity. 40, 217\u2013222 (2007).","journal-title":"Autoimmunity"},{"key":"74749_CR57","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1191\/096120301701549688","volume":"10","author":"AM Jacobi","year":"2001","unstructured":"Jacobi, A. M. et al. Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus. 10, 554\u2013561 (2001).","journal-title":"Lupus"},{"key":"74749_CR58","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1191\/096120398678920361","volume":"7","author":"P Jimena","year":"1998","unstructured":"Jimena, P. et al. Prolactin levels in patients with systemic lupus erythematosus: A case controlled study. Lupus. 7, 383\u2013386 (1998).","journal-title":"Lupus"},{"key":"74749_CR59","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3109\/03009749609069215","volume":"25","author":"B Ostendorf","year":"1996","unstructured":"Ostendorf, B. et al. Hyperprolactinemia in systemic lupus erythematosus? Scand. J. Rheumatol. 25, 97\u2013102 (1996).","journal-title":"Scand. J. Rheumatol."},{"key":"74749_CR60","first-page":"2216","volume":"28","author":"M Pacilio","year":"2001","unstructured":"Pacilio, M. et al. Elevated bioactive prolactin levels in systemic lupus erythematosus-association with disease activity. J. Rheumatol. 28, 2216\u20132221 (2001).","journal-title":"J. Rheumatol."},{"key":"74749_CR61","first-page":"2330","volume":"24","author":"J Rovensk\u00fd","year":"1997","unstructured":"Rovensk\u00fd, J. et al. Relationship between endocrine, immune, and clinical variables in patients with systemic lupus erythematosus. J. Rheumatol. 24, 2330\u20132334 (1997).","journal-title":"J. Rheumatol."},{"key":"74749_CR62","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/096120339300200507","volume":"2","author":"JF Sequeira","year":"1993","unstructured":"Sequeira, J. F. et al. Systemic lupus erythematosus: Sex hormones in male patients. Lupus. 2, 315\u2013317 (1993).","journal-title":"Lupus"},{"key":"74749_CR63","first-page":"476","volume":"23","author":"M Neidhart","year":"1996","unstructured":"Neidhart, M. Elevated serum prolactin or elevated prolactin\/cortisol ratio are associated with autoimmune processes in systemic lupus erythematosus and other connective tissue diseases. J. Rheumatol. 23, 476\u2013481 (1996).","journal-title":"J. Rheumatol."},{"key":"74749_CR64","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4103\/err.err_18_17","volume":"45","author":"MM Abdelaziz","year":"2018","unstructured":"Abdelaziz, M. M. et al. Influence of prolactin and estrogen on disease activity in patients with systemic lupus erythematosus. Egypt. Rheumatol. Rehabil. 45, 117\u2013123 (2018).","journal-title":"Egypt. Rheumatol. Rehabil."},{"key":"74749_CR65","first-page":"374","volume":"23","author":"A El-Garf","year":"1996","unstructured":"El-Garf, A., Salah, S., Shaarawy, M., Zaki, S. & Anwer, S. Prolactin hormone in juvenile systemic lupus erythematosus: a possible relationship to disease activity and CNS manifestations. J. Rheumatol. 23, 374\u2013377 (1996).","journal-title":"J. Rheumatol."},{"key":"74749_CR66","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.3923\/pjbs.2007.1984.1989","volume":"10","author":"AS Elwakkad","year":"2007","unstructured":"Elwakkad, A. S., Said, R. N., Muhammad, S. I., Saleh, M. T. & Elhamshary, A. Role for leptin and prolactin in human juvenile rheumatic diseases. Pak. J. Biol. Sci. 10, 1984\u20131989 (2007).","journal-title":"Pak. J. Biol. Sci."},{"key":"74749_CR67","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12969-023-00915-7","volume":"21","author":"HM Soliman","year":"2023","unstructured":"Soliman, H. M., Fahmy, B. S., Ali, M. G. & Shafie, E. S. Circulating prolactin level in Juvenile systemic lupus erythematosus and its correlation with disease activity: A case control study. Pediatr. Rheumatol. 21, 128 (2023).","journal-title":"Pediatr. Rheumatol."},{"key":"74749_CR68","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4103\/ejdv.ejdv_32_17","volume":"38","author":"MI Soliman","year":"2018","unstructured":"Soliman, M. I., Esawy, A. M. & Khashba, S. A. Role of prolactin in activity of systemic lupus erythematosus. Egypt. J. Dermatol. Venereol. 38, 23\u201328 (2018).","journal-title":"Egypt. J. Dermatol. Venereol."},{"key":"74749_CR69","first-page":"2084","volume":"22","author":"RW McMurray","year":"1995","unstructured":"McMurray, R. W., Weidensaul, D., Allen, S. H. & Walker, S. E. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J. Rheumatol. 22, 2084\u20132091 (1995).","journal-title":"J. Rheumatol."},{"key":"74749_CR70","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1191\/096120398678920334","volume":"7","author":"J Alvarez-Nemegyei","year":"1998","unstructured":"Alvarez-Nemegyei, J. et al. Bromocriptine in systemic lupus erythematosus: A double-blind, randomized, placebo-controlled study. Lupus. 7, 414\u2013419 (1998).","journal-title":"Lupus"},{"key":"74749_CR71","doi-asserted-by":"crossref","unstructured":"Qian, Q. et al. The effects of bromocriptine on preventing postpartum flare in systemic lupus erythematosus patients from South China. J. Immunol. Res. 316965 (2015).","DOI":"10.1155\/2015\/316965"},{"key":"74749_CR72","doi-asserted-by":"publisher","first-page":"e16977","DOI":"10.1016\/j.heliyon.2023.e16977","volume":"9","author":"MJ Mousavi","year":"2023","unstructured":"Mousavi, M. J., Alizadeh, A. & Ghotloo, S. Interference of B lymphocyte tolerance by prolactin in rheumatic autoimmune diseases. Heliyon. 9, e16977 (2023).","journal-title":"Heliyon"},{"key":"74749_CR73","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fimmu.2018.00073","volume":"9","author":"VV Borba","year":"2018","unstructured":"Borba, V. V., Zandman-Goddard, G. & Shoenfeld, Y. Prolactin and autoimmunity. Front. Immunol. 9, 73 (2018).","journal-title":"Front. Immunol."},{"key":"74749_CR74","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.4049\/jimmunol.147.11.3780","volume":"147","author":"R McMurray","year":"1991","unstructured":"McMurray, R., Keisler, D., Kanuckel, K., Izui, S. & Walker, S. E. Prolactin influences autoimmune disease activity in the female B\/W mouse. J. Immunol. 147, 3780\u20133787 (1991).","journal-title":"J. Immunol."},{"key":"74749_CR75","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1006\/clin.1994.1095","volume":"71","author":"R McMurray","year":"1994","unstructured":"McMurray, R., Keisler, D., Izui, S. & Walker, S. E. Hyperprolactinemia in male NZB\/NZW (B\/W) F1 mice: accelerated autoimmune disease with normal circulating testosterone. Clin. Immunol. Immunopathol. 71, 338\u2013343 (1994).","journal-title":"Clin. Immunol. Immunopathol."},{"key":"74749_CR76","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaut.2014.02.007","volume":"53","author":"V Jeganathan","year":"2014","unstructured":"Jeganathan, V., Peeva, E. & Diamond, B. Hormonal milieu at time of B cell activation controls duration of autoantibody response. J. Autoimmun. 53, 46\u201354 (2014).","journal-title":"J. Autoimmun."},{"key":"74749_CR77","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1172\/JCI200316530","volume":"111","author":"E Peeva","year":"2003","unstructured":"Peeva, E. et al. Prolactin modulates the naive B cell repertoire. J. Clin. Invest. 111, 275\u2013283 (2003).","journal-title":"J. Clin. Invest."},{"key":"74749_CR78","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1749-6632.1999.tb07629.x","volume":"876","author":"IC Chikanza","year":"1999","unstructured":"Chikanza, I. C. Prolactin and neuroimmunomodulation: in vitro and in vivo observations. Ann. N Y Acad. Sci. 876, 119\u2013130 (1999).","journal-title":"Ann. N Y Acad. Sci."},{"key":"74749_CR79","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0090-1229(90)90008-E","volume":"54","author":"M Blank","year":"1990","unstructured":"Blank, M., Palestine, A., Nussenblatt, R. & Shoenfeld, Y. Down-regulation of autoantibody levels of cyclosporine and bromocriptine treatment in patients with uveitis. Clin. Immunol. Immunopathol. 54, 87\u201397 (1990).","journal-title":"Clin. Immunol. Immunopathol."},{"key":"74749_CR80","doi-asserted-by":"publisher","first-page":"101324","DOI":"10.1016\/j.beem.2019.101324","volume":"33","author":"VV Borba","year":"2019","unstructured":"Borba, V. V., Zandman-Goddard, G. & Shoenfeld, Y. Prolactin and autoimmunity: the hormone as an inflammatory cytokine. Best Pract. Res. Clin. Endocrinol. Metab. 33, 101324 (2019).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"74749_CR81","doi-asserted-by":"publisher","first-page":"571229","DOI":"10.3389\/fendo.2021.571229","volume":"12","author":"H Yang","year":"2021","unstructured":"Yang, H. et al. Prolactin is associated with insulin resistance and beta-cell dysfunction in infertile women with polycystic ovary syndrome. Front. Endocrinol. (Lausanne). 12, 571229 (2021).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"74749_CR82","doi-asserted-by":"publisher","first-page":"e0175204","DOI":"10.1371\/journal.pone.0175204","volume":"12","author":"M Daimon","year":"2017","unstructured":"Daimon, M. et al. Association between serum prolactin levels and insulin resistance in non-diabetic men. PLoS One. 12, e0175204 (2017).","journal-title":"PLoS One"},{"key":"74749_CR83","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1161\/HYPERTENSIONAHA.109.132100","volume":"54","author":"GA Georgiopoulos","year":"2009","unstructured":"Georgiopoulos, G. A. et al. Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension. 54, 98\u2013105 (2009).","journal-title":"Hypertension"},{"key":"74749_CR84","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/eurjpc\/zwad112","volume":"30","author":"Y Shen","year":"2023","unstructured":"Shen, Y. et al. Association of prolactin with all-cause and cardiovascular mortality among patients with type 2 diabetes: a real-world study. Eur. J. Prev. Cardiol. 30, 1439\u20131447 (2023).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"74749_CR85","first-page":"3","volume":"39","author":"M Saleem","year":"2018","unstructured":"Saleem, M., Martin, H. & Coates, P. Prolactin biology and laboratory measurement: An update on physiology and current analytical issues. Clin. Biochem. Rev. 39, 3\u201316 (2018).","journal-title":"Clin. Biochem. Rev."},{"key":"74749_CR86","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.xfre.2023.05.005","volume":"4","author":"K Koniares","year":"2023","unstructured":"Koniares, K., Benadiva, C., Engmann, L., Nulsen, J. & Grow, D. Macroprolactinemia: A mini-review and update on clinical practice. F&S Rep. 4, 245\u2013250 (2023).","journal-title":"F&S Rep."},{"key":"74749_CR87","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","volume":"80","author":"ME Freeman","year":"2000","unstructured":"Freeman, M. E., Kanyicska, B., Lerant, A. & Nagy, G. Prolactin: Structure, function, and regulation of secretion. Physiol. Rev. 80, 1523\u20131631 (2000).","journal-title":"Physiol. Rev."},{"key":"74749_CR88","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2165\/00003495-199549020-00009","volume":"49","author":"CP Rains","year":"1995","unstructured":"Rains, C. P., Bryson, H. M. & Fitton, A. Cabergoline: A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs. 49, 255\u2013279 (1995).","journal-title":"Drugs"},{"key":"74749_CR89","doi-asserted-by":"publisher","first-page":"b381","DOI":"10.1136\/bmj.b381","volume":"338","author":"NM Martin","year":"2009","unstructured":"Martin, N. M., Tan, T. & Meeran, K. Dopamine agonists and hyperprolactinaemia. Bmj. 338, b381 (2009).","journal-title":"Bmj"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74749-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74749-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74749-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T15:02:48Z","timestamp":1733238168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74749-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["74749"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-74749-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4477148\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]},"assertion":[{"value":"25 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30143"}}